Literature DB >> 26450458

Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.

Victor H Jimenez-Zepeda1, Peter Duggan1, Paola Neri1, Ahsan Chaudhry1, Karen Murray1, Marcia Culham1, Joanne Luider2, Thomas Fourie3, Fariborz Rashid-Kolvear3, Nizar J Bahlis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26450458     DOI： 10.3109/10428194.2015.1085534

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs.

Authors:  Jun Zhang; Wenju Lu; Yuqin Chen; Qian Jiang; Kai Yang; Meichan Li; Ziyi Wang; Xin Duan; Lei Xu; Haiyang Tang; Dejun Sun; Jian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2016-07-13       Impact factor: 4.249

2.  VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.

Authors:  Kalyan Nadiminti; Kamal Kant Singh Abbi; Sarah L Mott; Lindsay Dozeman; Annick Tricot; Allyson Schultz; Sonya Behrends; Fenghuang Zhan; Guido Tricot
Journal:  Onco Targets Ther       Date:  2017-01-06       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.